Browsing by Author "Tamay A.T."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Giardiasis treatment in Turkish children with a single dose of ornidazole
    (2002) Özbilgin A.; Ertan P.; Yereli K.; Tamay A.T.; Kurt Ö.; Degerli K.; Balcioglu I.C.; Ok Ü.Z.; Onag A.
    This study was designed to compare the treatment efficacy of single dose of ornidazole with 5 d treatments of ornidazole and metronidazole in children with giardiasis. 175 children, between 2 and 15 y old, whose stool samples were found to be positive for Giardia lamblia cysts and/or trophozoites by either saline-Lugol, formalin-ethyl acetate or trichrome staining, were enrolled in the study. Of these children, 105 were treated with a single dose of ornidazole: 35 with 30 mg/kg, 35 with 25 mg/kg and 35 with 20 mg/kg; 35 were treated with 25 mg/kg per day of ornidazole for 5 d in 2 doses and 35 children were treated with 20 mg/kg per day metronidazole for 7 d in 3 doses. All cases were examined on the 7th, 10th and 14th days after treatment by the same methods; clinical symptoms were also evaluated. Giardia lamblia was eradicated in 34 of 35 (97%), 34 of 35 (97%) and 33 of 35 (94%) patients treated with 30, 25 and 20 mg/kg single doses of ornidazole, respectively. Eradication was achieved in all 35 patients treated with 25 mg/kg per day ornidazole for 5 d and in 31 of 35 (89%) patients treated with metronidazole. There was no statistically significant difference among doses of ornidazole (p > 0.05); however, all ornidazole treatment regimens were significantly more effective than metronidazole treatment (p < 0.05). No important side-effects were detected in any patients and clinical symptoms disappeared in all. Single-dose ornidazole treatment could be considered as a proper and effective alternative method for the treatment of giardiasis in children.
  • No Thumbnail Available
    Item
    Serological prevalence of Toxoplasma Gondii infection in children aged 1 month to 5 years in Manisa region, Western Turkey
    (2002) Yereli K.; Kasirga E.; Kilimcioglu A.; Ertan P.; Tamay A.T.; Özbilgin A.
    Objective: Toxoplasmosis is a protozoan infection caused by Toxoplasma gondii. Toxoplasma gondii infections are generally asymptomatic in immunocompetent cases. However, congenital toxoplasmosis may easily occur when seronegative women are being primarily infected during pregnancy. Routine serological testing is the only way of detecting toxoplasma antibodies in patients without any symptoms of toxoplasmosis. Design: In this study, seroprevalence rates according to age groups were determined in children living in Manisa region, Turkey. Materials and Methods: Sera were analyzed by indirect fluorescent antibody (IFA) and enzyme linked immunoassay (ELISA) methods. Results: Of the 200 children, 9 (4.5%) had only IgG, 2 (1.0%) had only IgM and 2 (1.0%) had both IgG and IgM types toxoplasma antibodies. Conclusion: The results of our study indicate that in Manisa region, Turkey, the antibody presence was increased with age and the overall toxoplasma antibody prevalence was 6.5% among children in the first five years of life.
  • No Thumbnail Available
    Item
    Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey
    (Elsevier, 2003) Deǧerli K.; Kilimcioǧlu A.A.; Kurt Ö.; Tamay A.T.; Özbilgin A.
    A murine toxoplasmosis model with Balb/C mice was used to investigate the therapeutic and prophylactic efficacy of azithromycin in a native strain of Toxoplasma gondii. Initially, seven groups - four studies and three controls - were established and 103 tachyzoites of this native strain of T. gondii were injected intraperitoneally to the mice in groups 1, 2, 3, 4 and 7. Azithromycin was given to groups 1-4 at different times of infection orally between 100 and 300 mg/kg/day for 10 days. Azithromycin was found to be effective at 200 mg/kg/day and above in the prophylaxis, at 250 mg/kg/day and above in the treatment of toxoplasmosis. These results suggest that azithromycin is effective in the prophylaxis and early infection of a highly virulent strain of T. gondii, and it doubled the survival time in the late infection. Azithromycin could be an alternative treatment regimen for human toxoplasmosis, if supported by further clinical investigations. © 2003 Elsevier B.V. All rights reserved.